{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:40:34Z","timestamp":1791186034267,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The JAKs receive continued interest as therapeutic targets for autoimmune, inflammatory, and oncological diseases. JAKs play critical roles in the development and biology of the hematopoietic system, as evidenced by mouse and human genetics. JAK1 is critical for the signal transduction of many type I and type II inflammatory cytokine receptors. In a search for JAK small molecule inhibitors, GLPG0634 was identified as a lead compound belonging to a novel class of JAK inhibitors. It displayed a JAK1\/JAK2 inhibitor profile in biochemical assays, but subsequent studies in cellular and whole blood assays revealed a selectivity of \u223c30-fold for JAK1- over JAK2-dependent signaling. GLPG0634 dose-dependently inhibited Th1 and Th2 differentiation and to a lesser extent the differentiation of Th17 cells in vitro. GLPG0634 was well exposed in rodents upon oral dosing, and exposure levels correlated with repression of Mx2 expression in leukocytes. Oral dosing of GLPG0634 in a therapeutic set-up in a collagen-induced arthritis model in rodents resulted in a significant dose-dependent reduction of the disease progression. Paw swelling, bone and cartilage degradation, and levels of inflammatory cytokines were reduced by GLPG0634 treatment. Efficacy of GLPG0634 in the collagen-induced arthritis models was comparable to the results obtained with etanercept. In conclusion, the JAK1 selective inhibitor GLPG0634 is a promising novel therapeutic with potential for oral treatment of rheumatoid arthritis and possibly other immune-inflammatory diseases.<\/jats:p>","DOI":"10.4049\/jimmunol.1201348","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T04:46:35Z","timestamp":1378356395000},"page":"3568-3577","source":"Crossref","is-referenced-by-count":222,"title":["Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases"],"prefix":"10.1093","volume":"191","author":[{"given":"Luc","family":"Van Rompaey","sequence":"first","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Galien","sequence":"additional","affiliation":[{"name":"Departement of In Vivo Pharmacology and Translational Sciences, Galapagos SASU , 93230 Romainville,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M","family":"van der Aar","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Clement-Lacroix","sequence":"additional","affiliation":[{"name":"Departement of In Vivo Pharmacology and Translational Sciences, Galapagos SASU , 93230 Romainville,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Nelles","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Smets","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u00ean","family":"Lepescheux","sequence":"additional","affiliation":[{"name":"Departement of In Vivo Pharmacology and Translational Sciences, Galapagos SASU , 93230 Romainville,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Christophe","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Conrath","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Vandeghinste","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Vayssiere","sequence":"additional","affiliation":[{"name":"Departement of In Vivo Pharmacology and Translational Sciences, Galapagos SASU , 93230 Romainville,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"De Vos","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Brys","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben","family":"van \u2019t Klooster","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean H M","family":"Feyen","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Menet","sequence":"additional","affiliation":[{"name":"Departement of In Vitro Pharmacology, Galapagos NV , 2800 Mechelen,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"2025032405401988800_r1","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","article-title":"Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease","volume":"44","author":"O\u2019Sullivan","year":"2007","journal-title":"Mol. Immunol."},{"key":"2025032405401988800_r2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.semcdb.2008.07.002","article-title":"JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies","volume":"19","author":"Vainchenker","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"key":"2025032405401988800_r3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"2025032405401988800_r4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrd1441","article-title":"A new modality for immunosuppression: targeting the JAK\/STAT pathway","volume":"3","author":"O\u2019Shea","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025032405401988800_r5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O\u2019Shea","year":"2012","journal-title":"Immunity"},{"key":"2025032405401988800_r6","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/ar2365","article-title":"Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis","volume":"10","author":"Milici","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"2025032405401988800_r7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejphar.2007.12.024","article-title":"The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia","volume":"582","author":"Kudlacz","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"2025032405401988800_r8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"2025032405401988800_r9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J. Inflamm. (Lond.)"},{"key":"2025032405401988800_r10","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J. Immunol."},{"key":"2025032405401988800_r11","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2025032405401988800_r12","first-page":"S911","article-title":"A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis","volume":"62","author":"Greenwald","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2025032405401988800_r13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O\u2019Shea","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2025032405401988800_r14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.chembiol.2011.03.002","article-title":"JAK3 specific kinase inhibitors: when specificity is not enough","volume":"18","author":"Cox","year":"2011","journal-title":"Chem. Biol."},{"key":"2025032405401988800_r15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.chembiol.2011.01.012","article-title":"Jak1 has a dominant role over Jak3 in signal transduction through \u03b3c-containing cytokine receptors","volume":"18","author":"Haan","year":"2011","journal-title":"Chem. Biol."},{"key":"2025032405401988800_r16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1021\/jm101157q","article-title":"Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family","volume":"54","author":"Thoma","year":"2011","journal-title":"J. Med. Chem."},{"key":"2025032405401988800_r17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2010.11.043","article-title":"Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production","volume":"127","author":"Newcomb","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025032405401988800_r18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/ni.1613","article-title":"A critical function for transforming growth factor-\u03b2, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses","volume":"9","author":"Volpe","year":"2008","journal-title":"Nat. Immunol."},{"key":"2025032405401988800_r19","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nprot.2007.173","article-title":"Collagen-induced arthritis","volume":"2","author":"Brand","year":"2007","journal-title":"Nat. Protoc."},{"key":"2025032405401988800_r20","doi-asserted-by":"crossref","first-page":"e1000669","DOI":"10.1371\/journal.pcbi.1000669","article-title":"A variant of TNFR2-Fc fusion protein exhibits improved efficacy in treating experimental rheumatoid arthritis","volume":"6","author":"Yang","year":"2010","journal-title":"PLOS Comput. Biol."},{"key":"2025032405401988800_r21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjp.0707165","article-title":"Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents","volume":"150","author":"Lin","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"2025032405401988800_r22","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"2025032405401988800_r23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2003.11.031","article-title":"Induction of Mx-2 in rat liver by toxic injury","volume":"40","author":"Batusic","year":"2004","journal-title":"J. Hepatol."},{"key":"2025032405401988800_r24","doi-asserted-by":"crossref","first-page":"8626","DOI":"10.1128\/JVI.00303-10","article-title":"Temporal and spatial resolution of type I and III interferon responses in vivo","volume":"84","author":"Pulverer","year":"2010","journal-title":"J. Virol."},{"key":"2025032405401988800_r25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"2025032405401988800_r26","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"2025032405401988800_r27","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/ard.2007.076430","article-title":"Utility of animal models for identification of potential therapeutics for rheumatoid arthritis","volume":"67","author":"Hegen","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"2025032405401988800_r28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/B978-0-444-62652-3.00004-1","article-title":"Advances in the discovery of selective JAK inhibitors","volume":"52","author":"Menet","year":"2013","journal-title":"Prog. Med. Chem."},{"key":"2025032405401988800_r29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbrc.2010.04.141","article-title":"Expression, purification, and characterization of TYK-2 kinase domain, a member of the Janus kinase family","volume":"396","author":"Korniski","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2025032405401988800_r30","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1074\/jbc.M109165200","article-title":"SH2-B family members differentially regulate JAK family tyrosine kinases","volume":"277","author":"O\u2019Brien","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2025032405401988800_r31","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.2741\/3051","article-title":"Protein tyrosine phosphatases in the JAK\/STAT pathway","volume":"13","author":"Xu","year":"2008","journal-title":"Front. Biosci."},{"key":"2025032405401988800_r32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.semcdb.2008.07.010","article-title":"SOCS regulation of the JAK\/STAT signalling pathway","volume":"19","author":"Croker","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"key":"2025032405401988800_r33","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1172\/JCI42032","article-title":"Lnk constrains myeloproliferative diseases in mice","volume":"120","author":"Bersenev","year":"2010","journal-title":"J. Clin. Invest."},{"key":"2025032405401988800_r34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrd2805","article-title":"Averting inflammation by targeting the cytokine environment","volume":"9","author":"Kopf","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025032405401988800_r35","first-page":"2210","article-title":"GLPG0634 shows selective inhibition of JAK1 and maintained JAK-STAT suppression in healthy volunteers","volume":"63","author":"Vanhoutte","year":"2011","journal-title":"Arthritis Rheum."},{"key":"2025032405401988800_r36","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1600-6143.2008.02307.x","article-title":"Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics","volume":"8","author":"van Gurp","year":"2008","journal-title":"Am. J. Transplant."},{"key":"2025032405401988800_r37","first-page":"1331","article-title":"Once daily high dose regimens of GLPG0634 in healthy volunteers are safe and provide continuous inhibition of JAK1 but not JAK2","volume":"64","author":"Namour","year":"2012","journal-title":"Arthritis Rheum."},{"key":"2025032405401988800_r38","first-page":"2489","article-title":"Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GLPG0634","volume":"64","author":"Vanhoutte","year":"2012","journal-title":"Arthritis Rheum."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/191\/7\/3568\/62511127\/1201348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/191\/7\/3568\/62511127\/1201348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T05:27:24Z","timestamp":1742880444000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/191\/7\/3568\/7989589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1201348","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,10]]},"published":{"date-parts":[[2013,10,1]]}}}